Iovancebiotherapeutics
Senior Director, Pipeline Commercial Strategy
Remote. Posted 22 days ago
The role
The Senior Director, Pipeline Commercial Strategy owns the commercial assessment of pipeline assets. This includes market sizing, target product profiles, and competitive analysis to shape portfolio and indication strategy.
What you will do
- Own commercial assessment of pipeline assets and indication expansions
- Build market sizing and addressable market analyses
- Develop and maintain target product profiles for pipeline assets
- Own competitive analysis and scenario planning for pipeline indications
- Drive portfolio prioritization, forecasting, and commercial recommendations
- Lead early commercial assessments for pipeline assets and business development
- Provide commercial input on tumor target, indication, and launch market selection
- Partner with Clinical Development to influence clinical milestones and trial design
- Own launch trackers, readiness scorecards, risk registers, and milestone dashboards
Required qualifications
- Bachelor's degree
- 10+ years of biopharmaceutical, biotech, oncology, cell therapy, specialty medicine, commercial strategy, launch planning, brand strategy, market access, consulting, or related experience
- Hands-on experience building market sizing and addressable market models, target product profiles, competitive assessments, and reimbursement or payer analyses for oncology or cell therapy assets
- Deep commercial domain expertise in shaping commercial strategy and making market-facing decisions
- Demonstrated ability to lead complex cross-functional initiatives and influence senior stakeholders
- Track record of leading product launches, new product planning, commercial assessments, forecasting, portfolio strategy, or launch readiness
Nice to have
- Advanced degree such as MBA, MPH, PharmD, PhD, or relevant graduate degree
About the company
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. The company operates as an end-to-end cell therapy company with U.S.-based manufacturing.